NcXHF

APPROACHES IN BRAIN METASTASES
22. Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain
radiation therapy and stereotactic radiosurgery alone versus WBRT and
SRS with temozolomide or erlotinib for non-small cell lung cancer and
1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J
Radiat Oncol Biol Phys. 2013;85:1312-1318.
23. Gerber NK, Yamada Y, Rimner A, et al. Erlotinib versus radiation therapy
for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Int J Radiat Oncol Biol Phys. 2014;89:322-329.
24. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefıtinib in patients with
brain metastases from non-small-cell lung cancer: a prospective trial.
Ann Oncol. 2004;15:1042-1047.
25. Park SJ, Kim HT, Lee DH, et al. Effıcacy of epidermal growth factor
receptor tyrosine kinase inhibitors for brain metastasis in non-small cell
lung cancer patients harboring either exon 19 or 21 mutation. Lung
Cancer. 2012;77:556-560.
26. Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in
patients with advanced non-small-cell lung cancer and asymptomatic
brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013;24:
993-999.
27. Fan Y, Xu X, Xie C. EGFR-TKI therapy for patients with brain metastases
from non-small-cell lung cancer: a pooled analysis of published data.
Onco Targets Ther. 2014;7:2075-2084.
28. Masuda T, Hattori N, Hamada A, et al. Erlotinib effıcacy and cerebrospinal
fluid concentration in patients with lung adenocarcinoma developing
leptomeningeal metastases during gefıtinib therapy. Cancer
Chemother Pharmacol. 2011;67:1465-1469.
29. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase
inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-
1703.
30. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in
patients with advanced ALK-rearranged non-small-cell lung cancer and
brain metastases. J Clin Oncol. Epub 2015 Jan 26.
31. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin
Oncol. 2004;22:3608-3617.
32. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of
breast cancer subtypes. J Clin Oncol. 2010;28:3271-3277.
33. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases
from breast cancer in the trastuzumab era. J Clin Oncol. 2005;23:
2114-2116; author reply, 2116-2117.
34. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of
89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients
with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-
592.
35. Park YH, Park MJ, Ji SH, et al. Trastuzumab treatment improves brain
metastasis outcomes through control and durable prolongation of systemic
extracranial disease in HER2-overexpressing breast cancer patients.
Br J Cancer. 2009;100:894-900.
36. Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding
to primary systemic therapy with T-DM1. J Neurooncol. 2014;
116:205-206.
37. Torres S, Maralani P, Verma S. Activity of T-DM1 in HER2-positive
central nervous system breast cancer metastases. BMJ Case Rep. 2014;
2014:bcr2014205680.
38. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth
of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;
100:1092-1103.
39. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain
metastases in patients with human epidermal growth factor receptor
2-positive breast cancer. J Clin Oncol. 2008;26:1993-1999.
40. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in
patients with previously untreated brain metastases from HER2-
positive metastatic breast cancer (LANDSCAPE): a single-group phase
2 study. Lancet Oncol. 2013;14:64-71.
41. Whole-brain radiation therapy with or without lapatinib ditosylate
in treating patients with brain metastasis from HER2-positive
breastcancer.https://clinicaltrials.gov/ct2/show/NCT01622868?term
NCT01622868&rank1. Accessed January 28, 2015.
42. HKI-272 for HER2-positive breast cancer and brain metastases. https://
clinicaltrials.gov/ct2/show/NCT01494662?termNCT01494662&rank
1. Accessed January 28, 2015.
43. NCT01441596. Lux Breast 3; Afatinib Alone or in Combination
With Vinorelbine in Patients With Human Epidermal Growth Factor
Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain
Metastases. https://clinicaltrials.gov/ct2/show/NCT01441596?term
NCT01441596&rank1. Accessed January 28, 2015.
44. NCT01921335. ARRY-380 Trastuzumab for Breast w/ Brain Mets. https://
clinicaltrials.gov/ct2/show/NCT01921335?termNCT01921335&rank1. Accessed
January 28, 2015.
45. Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in
melanoma patients with brain metastases. Cancer. 2011;117:1687-1696.
46. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent
prognostic factor in metastatic melanoma. Cancer. 2012;118:
4014-4023.
47. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with
melanoma, untreated brain metastases, and other solid tumours: a
phase 1 dose-escalation trial. Lancet. 2012;379:1893-1901.
48. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with
Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the
brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet
Oncol. 2012;13:1087-1095.
49. NCT01721603. A Phase 2 Prospective Trial of Dabrafenib with Stereotactic
Radiosurgery in BRAFV600E Melanoma Brain Metastases.
https://clinicaltrials.gov/ct2/show/NCT01721603. Accessed January
28, 2015.
50. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients
with BRAF(V600) mutation-positive melanoma with symptomatic
brain metastases: fınal results of an open-label pilot study. Eur J Cancer.
2014;50:611-621.
51. Kefford R MM, Arance A. Vemurafenib in metastatic melanoma patients
with brain metastases: an open-label, single-arm, phase 2, multicenter
study. Presented at: Society for Melanoma Research Congress;
2013; Philadelphia, PA.
52. Heimberger AB, Bigner DD, Sampson JH. Biological principles of brain
tumor immunotherapy. In Liau, LM, Becker DP, Cloughesy TF, Bigner
DD. Brain Tumor Immunotherapy. Totowa, NJ: Humana Press, 2001;
101-130.
53. Engelhardt B. The blood-central nervous system barriers actively control
immune cell entry into the central nervous system. Curr Pharm Des.
2008;14:1555-1565.
54. Prins RM, Vo DD, Khan-Farooqi H, et al. NK and CD4 cells collaborate
to protect against melanoma tumor formation in the brain. J Immunol.
2006;177:8448-8455.
55. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients
with metastatic melanoma: evaluation of intensive myeloablative
chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
56. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab
in patients with metastatic melanoma. N Engl J Med. 2010;363:
711-723.
57. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with
melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol.
2012;13:459-465.
58. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 73